Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell of proximal tubule | 8 studies | 23% ± 4% | |
epithelial cell | 8 studies | 30% ± 15% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 7 studies | 20% ± 3% | |
enterocyte | 6 studies | 38% ± 10% | |
kidney loop of Henle epithelial cell | 5 studies | 20% ± 3% | |
hepatocyte | 5 studies | 43% ± 20% | |
goblet cell | 4 studies | 20% ± 3% | |
astrocyte | 4 studies | 22% ± 5% | |
intestinal crypt stem cell | 3 studies | 26% ± 2% | |
progenitor cell | 3 studies | 29% ± 7% | |
ciliated cell | 3 studies | 19% ± 3% | |
fibroblast | 3 studies | 16% ± 1% | |
regulatory T cell | 3 studies | 25% ± 8% | |
enteroendocrine cell | 3 studies | 23% ± 8% | |
endothelial cell | 3 studies | 17% ± 2% | |
transit amplifying cell | 3 studies | 25% ± 12% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 4 studies | 22% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 2116.69 | 650 / 653 | 99% | 45.18 | 601 / 605 |
prostate | 99% | 4746.87 | 242 / 245 | 100% | 93.45 | 500 / 502 |
kidney | 100% | 5946.71 | 89 / 89 | 98% | 50.00 | 883 / 901 |
liver | 100% | 10357.02 | 226 / 226 | 97% | 69.77 | 393 / 406 |
intestine | 100% | 3705.07 | 962 / 966 | 90% | 28.20 | 476 / 527 |
adrenal gland | 100% | 6446.24 | 257 / 258 | 90% | 28.91 | 206 / 230 |
stomach | 99% | 1622.62 | 354 / 359 | 88% | 27.89 | 252 / 286 |
breast | 98% | 1958.63 | 449 / 459 | 88% | 28.28 | 984 / 1118 |
ovary | 100% | 2860.31 | 180 / 180 | 74% | 12.05 | 320 / 430 |
pancreas | 100% | 2984.80 | 328 / 328 | 73% | 13.46 | 130 / 178 |
uterus | 100% | 2049.92 | 170 / 170 | 73% | 16.35 | 333 / 459 |
esophagus | 99% | 2150.58 | 1432 / 1445 | 73% | 13.22 | 133 / 183 |
brain | 96% | 1069.91 | 2538 / 2642 | 64% | 10.35 | 454 / 705 |
bladder | 100% | 1780.00 | 21 / 21 | 55% | 12.94 | 277 / 504 |
lung | 79% | 702.15 | 459 / 578 | 67% | 10.99 | 769 / 1155 |
skin | 80% | 2458.08 | 1446 / 1809 | 59% | 11.89 | 280 / 472 |
spleen | 99% | 1046.52 | 239 / 241 | 0% | 0 | 0 / 0 |
adipose | 96% | 1375.64 | 1152 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 30.25 | 76 / 80 |
blood vessel | 93% | 1023.74 | 1241 / 1335 | 0% | 0 | 0 / 0 |
heart | 93% | 1446.70 | 797 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 26.97 | 36 / 45 |
muscle | 77% | 685.88 | 617 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 48% | 6.48 | 14 / 29 |
peripheral blood | 26% | 221.26 | 237 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0090181 | Biological process | regulation of cholesterol metabolic process |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0097176 | Biological process | epoxide metabolic process |
GO_0046839 | Biological process | phospholipid dephosphorylation |
GO_0046272 | Biological process | stilbene catabolic process |
GO_0016311 | Biological process | dephosphorylation |
GO_0009636 | Biological process | response to toxic substance |
GO_0042632 | Biological process | cholesterol homeostasis |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005777 | Cellular component | peroxisome |
GO_0005829 | Cellular component | cytosol |
GO_0005782 | Cellular component | peroxisomal matrix |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0004301 | Molecular function | epoxide hydrolase activity |
GO_0033885 | Molecular function | 10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activity |
GO_0015643 | Molecular function | toxic substance binding |
GO_0052642 | Molecular function | lysophosphatidic acid phosphatase activity |
GO_0042577 | Molecular function | lipid phosphatase activity |
GO_0016791 | Molecular function | phosphatase activity |
Gene name | EPHX2 |
Protein name | Bifunctional epoxide hydrolase 2 [Includes: Cytosolic epoxide hydrolase 2 (CEH) (EC 3.3.2.10) (Epoxide hydratase) (Soluble epoxide hydrolase) (SEH); Lipid-phosphate phosphatase (EC 3.1.3.76)] Epoxide hydrolase 2 |
Synonyms | |
Description | FUNCTION: Bifunctional enzyme . The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides . Plays a role in xenobiotic metabolism by degrading potentially toxic epoxides (By similarity). Also determines steady-state levels of physiological mediators . .; FUNCTION: Bifunctional enzyme . The N-terminal domain has lipid phosphatase activity, with the highest activity towards threo-9,10-phosphonooxy-hydroxy-octadecanoic acid, followed by erythro-9,10-phosphonooxy-hydroxy-octadecanoic acid, 12-phosphonooxy-octadec-9Z-enoic acid and 12-phosphonooxy-octadec-9E-enoic acid . Has phosphatase activity toward lyso-glycerophospholipids with also some lower activity toward lysolipids of sphingolipid and isoprenoid phosphates . . |
Accessions | H0YAW7 ENST00000521780.5 [P34913-3] ENST00000518328.5 ENST00000380476.7 [P34913-2] P34913 ENST00000521684.1 ENST00000517536.5 E5RFU2 E5RFH6 ENST00000518379.5 E5RI53 ENST00000521400.6 [P34913-1] |